Peritonitis and automated peritoneal dialysis: A therapeutic conundrum?

Peritoneal Dialysis International

Volumn 25, Issue 2, 2005, Pages 142-145

  Troidle, Laura ^a   Finkelstein, Fredric O ^a  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZTREONAM; CEFAZOLIN; CEFTAZIDIME; CIPROFLOXACIN; GENTAMICIN; VANCOMYCIN;

ARTICLE; AUTOMATION; BIOFILM; CONTINUOUS AMBULATORY PERITONEAL DIALYSIS; DIALYSATE; GRAM NEGATIVE BACTERIUM; GRAM POSITIVE BACTERIUM; HUMAN; KIDNEY FAILURE; MINIMUM INHIBITORY CONCENTRATION; MORBIDITY; MORTALITY; MYCOSIS; PERITONEAL CATHETER; PERITONEAL DIALYSIS; PERITONITIS; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL;

EID: 16844385840     PISSN: 08968608     EISSN: None     Source Type: Journal    
DOI: 10.1177/089686080502500206     Document Type: Article

References (36)

1. Krishnan M, Thodis E, Ikonomopoulos D, Vigden E, Chu M, Bargman JM, et al. Predictors of outcome following bacterial peritonitis in peritoneal dialysis. Perit Dial Int 2002; 22:563-5.
2. Fried LF, Bernardini J, Johnston JR, Piraino B. Peritonitis influences mortality in peritoneal dialysis patients. J Am Soc Nephrol 1996; 7:2176-82.
3. United States Renal Data System. USRDS 2004 Annual Data Report. Bethesda, MD: National Institutes of Heath, National Institute of Diabetes and Digestive and Kidney Diseases; 2004.
4. Mendelssohn DC, Langlois N, Blake PC. Peritoneal dialysis in Ontario: a natural experience in physician reimbursement methodology. Perit Dial Int 2004; 24:531-7.
5. Mettang T. Changes in dialysis reimbursement regulations in Germany. Perit Dial Int 2004; 24:526-7.
6. Little J, Irwin A, Marshall T, Rayner H, Smith S. Predicting a patient's choice of dialysis modality: experience in a United Kingdom renal department. Am J Kidney Dis 2001; 37:981-6.
7. Jassal SV, Krishna G, Mallick NP, Mendelssohn DC. Attitudes of British Isles nephrologists towards dialysis modality selection: a questionnaire study. Nephrol Dial Transplant 2002; 17:474-7.
8. Mendelssohn DC, Mullaney SR, Jung B, Blake P, Mehta RL. What do American nephrologists think about dialysis modality selection? Am J Kidney Dis 2001; 37:22-9.
9. Jung B, Blake P, Mehta RL, Mendelssohn DC. Attitudes of Canadian nephrologists toward dialysis modality selection. Perit Dial Int 1999; 19:263-8.
10. Troidle L, Kliger AS, Finkelstein FO. Factors influencing CPD utilization in Network #1: New England [Abstract]. J Am Soc Nephrol 2004; 15:354A.
11. Troidle L, Gorban-Brennan N, Kliger A, Finkelstein F. Differing outcomes of gram-positive and gram-negative peritonitis. Am J Kidney Dis 1998; 32:623-8.
12. Gorban-Brennan N, Troidle L, Kliger AS, Finkelstein FO. Peritonitis and its relationship with death in a large CPD cohort [Abstract]. Perit Dial Int 1999; 19(Suppl 1):S31.
13. Juergensen PJ, Murphy AL, Kliger AS, Finkelstein FO. Increasing the dialysis volume and frequency in a fixed period of time in CPD patients: the effect on Kpt/V and creatinine clearance. Perit Dial Int 2002; 22:693-7.
14. Gorban-Brennan N, Kliger A, Finkelstein F. Once-daily intraperitoneal efazolin and oral ciprofloxacin as empiric therapy for the treatment of peritonitis. Adv Perit Dial 1999; 15:213-16.
15. Troidle LK, Gorban-Brennan N, Kliger AS, Finkelstein FO. Continuous cycler therapy, manual peritoneal dialysis therapy, and peritonitis. Adv Perit Dial 1998; 14:137-41.
16. Yishak A, Bernardini J, Fried L, Piraino B. The outcome of peritonitis in patients on automated peritoneal dialysis. Adv Perit Dial 2001; 17:205-8.
17. Brown EA, Davies SJ, Rutherford P, Meeus F, Riegel W, Divino-Filho JC, et al.; EAPOS Group. Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol 2003; 14: 2948-57.
18. Lye WC, van der Straaten JC, Leong SO, Sivaraman P, Tan SH, Tan CC, et al. Once-daily intraperitoneal gentamicin is effective therapy for gram-negative CAPD peritonitis. Perit Dial Int 1999; 19:357-60.
19. Manley HJ, Bailie GR, Asher RD, Eisele G, Frye RF. Pharmacokinetics of intraperitoneal cefazolin in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1999; 19:65-70.
20. Wong KM, Chan YH, Cheung CY, Chak WL, Choi KS, Leung SH, et al. Cefepime versus vancomycin plus netilmicin therapy for continuous ambulatory peritoneal dialysis-associated peritonitis. Am J Kidney Dis 2001; 38:127-31.
21. Vas SI. Single daily dose of aminoglycosides in the treatment of continuous ambulatory peritoneal dialysis peritonitis. Perit Dial Int l993; 13(Suppl 2):S355-6.
22. Morse GD, Farolino DF, Apicella MA, Walshe JJ. Comparative study of intraperitoneal and intravenous vancomycin pharmacokinetics during continuous ambulatory peritoneal dialysis. Antimicrob Agents Chemother 1987; 31: 173-7.
23. Manley HJ, Bailie GR, Frye RF, McGoldrick MD. Intravenous vancomycin pharmacokinetics in automated peritoneal dialysis patients. Perit Dial Int 2001; 21:378-85.
24. Manley HJ, Bailie GR, Frye R, Hess LD, McGoldrick MD. Pharmacokinetics of intermittent intravenous cefazolin and tobramycin in patients treated with automated peritoneal dialysis. J Am Soc Nephrol 2000; 11:1310-16.
25. Elwell RJ, Manley HJ, Bailie GR. Comparison of intraperitoneal ceftazidime pharmacokinetics in CAPD and APD patients [Abstract]. J Am Soc Nephrol 2002; 13:383A.
26. Yeung SM, Walker SE, Tailor SAN, Awdishu L, Tobe S, Yassa T. Pharmacokinetics of oral ciprofloxacin in continuous cycling peritoneal dialysis. Perit Dial Int 2004; 24:447-53.
27. Fielding RE, Clemenger M, Goldberg L, Brown EA. Treatment and outcome of peritonitis in automated peritoneal dialysis, using a once-daily cefazolin-based regimen. Perit Dial Int 2002; 22:345-9.
28. Goldberg L, Clemenger M, Azadian B, Brown EA. Initial treatment of peritoneal dialysis peritonitis without vancomycin with a once-daily cefazolin-based regimen. Am J Kidney Dis 2001; 37:49-55.
29. Costerton JW, Stewart PS, Greenberg EP. Bacterial biofilms: a common cause of persistent infections. Science 1999; 284:1318-22.
30. Costerton W, Veeh R, Shirtliff M, Pasmore M, Post C, Ehrlich G. The application of biofilm science to the study and control of chronic bacterial infections. J Clin Invest 2003; 112: 1466-77.
31. Sepandj F, Ceri H, Gibb AP, Read RR, Olson M. Biofilm infections in peritoneal dialysis-related peritonitis: comparison of standard MIC and MBEC in evaluation of antibiotic sensitivity of coagulase-negative staphylococci. Perit Dial Int 2003; 23:77-9.
32. Sepandj F, Ceri H, Gibb A, Read R, Olson M. Minimum inhibitory concentration (MIC) versus minimum biofilm eliminating concentration (MBEC) evaluation of antibiotic sensitivity of gram-negative bacilli causing peritonitis. Perit Dial Int 2004; 24:65-7.
33. Khaled GH, Finkelstein FO, Carey HB, Wardlaw SC, Kliger AS, Edberg SC. Method for studying development of colonization and infection of dialysis catheters. Adv Perit Dial 2001; 17:163-71.
34. Troidle L, Gorban-Brennan N, Khaled GH, Edberg SC, Finkelstein FO. Biofilm and its clinical significance [Abstract]. Perit Dial Int 2002; 22(Suppl 1):S41.
35. Dasgupta MK. Biofilms and infection in dialysis patients. Semin Dial 2002; 15:338-46.
36. Finkelstein ES, Jekel J, Troidle L, Gorban-Brennan N, Finkelstein FO, Bia FJ. Patterns of infection in patients maintained on long-term peritoneal dialysis therapy with multiple episodes of peritonitis. Am J Kidney Dis 2002; 39:1278-86.